NEW YORK – OncoHelix said Wednesday that it has entered a partnership with AstraZeneca Canada to deliver liquid biopsy testing for metastatic castration-resistant prostate cancer (mCRPC) patients in provinces that lack public funding for the type of genomic profiling the company offers.
According to the companies, testing will be performed in OncoHelix's laboratory for a limited time, supported by a collaboration between AstraZeneca and Merck.
Financial details were not disclosed.
OncoHelix said a blood-based testing option is especially crucial for mCRPC patients, who often lack sufficient tissue biopsy material or who are progressing so fast they can't afford to wait for a new sample to be taken for tissue-based testing.
The company offers a liquid biopsy sequencing panel developed by Memorial Sloan Kettering, called MSK-ACCESS, coupled with Sophia Genetics' Sophia DDM software support.
MSK and Sophia launched their combined kit for disseminated use last year. It analyzes 146 cancer-related genes, reporting actionable insights to physicians.